Removal of basiliximab by plasmapheresis.
Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.
Okechukwu
C N
CN
Division of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Meier-Kriesche
H U
HU
Armstrong
D
D
Campbell
D
D
Gerbeau
C
C
Kaplan
B
B
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000097:blood*; D000077552:Basiliximab; D001781:Blood Component Removal; D016572:Cyclosporine / Q000009:adverse effects*; D016903:Drug Monitoring; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood*; D016031:Liver Transplantation / Q000276:immunology; D008875:Middle Aged; D010956:Plasmapheresis / Q000379:methods*; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab